Driehaus Capital TPTX Position
ActiveDriehaus Capital increased their position in Turning Point Therapeutics Inc. (TPTX) in Q4 2025, holding $52.2M worth of shares across 481,834 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
1 other tracked fund also holds TPTX.
There is an upcoming Phase 2 readout for Oral repotrectinib (TPX-0005) in 167 days (Sep 30, 2026), making the timing of Driehaus's position particularly relevant.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Full company profile →Driehaus Capital TPTX Position History
Frequently Asked Questions
Does Driehaus Capital own TPTX?
Yes. As of Q4 2025, Driehaus Capital holds 481,834 shares of Turning Point Therapeutics Inc. (TPTX) valued at $52.2M. This data comes from their SEC 13F filing.
How many hedge funds own TPTX?
2 specialist biotech hedge funds currently hold TPTX, including Boxer Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy TPTX?
Driehaus Capital's position in TPTX was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's TPTX position increasing or decreasing?
Driehaus Capital increased their TPTX position in the most recent quarter, adding 76,790 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TPTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →